Palabras clave
Cómo citar
Resumen
Objetivo: Evaluar la efectividad de los análogos de somatostatina, lanreótide, octreótide y pasireótide en el control de GH, IGF-1 y tamaño tumoral en una cohorte pacientes con acromegalia. Materiales y métodos: estudio observacional, analítico, tipo cohorte retrospectiva, unicéntrico, de pacientes con acromegalia en un centro de alta complejidad en la ciudad de Cali – Colombia. Para evaluar la efectividad, se usó análisis bivariado, se hicieron tablas de contingencia, chi-cuadrado, ANOVA de una vía en un modelo lineal general de medidas repetidas de una y dos vías, con un ? ? 0.05. Resultados: Se incluyeron 29 pacientes, 52% eran hombres. La edad promedio fue de 54.8 años (rango: 28-79 años). Los niveles promedio de GH e IGF-1 fueron de 13.7ng/dl y 776 ng/ml, respectivamente. La media de tamaño tumoral fue de 17.2 mm. Se encontró disminución de los niveles de GH e IGF-1 en todos los pacientes, independientemente del medicamento recibido. Se observó disminución del tamaño tumoral en el seguimiento a 12 meses del 41.6%. En cuanto a los criterios de control adecuado, el 27.6% de pacientes lo alcanzó tras un año de tratamiento, de los cuales, 62.5% eran mujeres y 37.5% se encontraban recibiendo pasireótide, el resto recibió lanreótide. Conclusiones: Los análogos de somatostatina fueron efectivos en la disminución de los niveles de GH, IGF -1 y tamaño tumoral, tras un seguimiento de 12 meses.
Citas
Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CMG, Pinedo AC, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19(4):448–57.
Caamaño-Villafañe P, Gill-Barretoa S, Ramos-Villegas Y, Corrales-Santander H, Pacheco-Hernández A, Picón Y, et al. Acromegalia y adenomas hipofisiarios: una revisión de la literatura. Cienc e Innovación en Salud [Internet]. 2019;e76:1–9. Available from: http://revistas.unisimon.edu.co/index.php/innovacionsalud/article/view/3618
Zahr R, Fleseriu M. Updates in Diagnosis and Treatment of Acromegaly. Eur Endocrinol. 2018;14(2):57.
Pérez AV, Cañón LA, Vanegas EP, Rojas W, Lammoglia J, Pautt T. Efectividad y seguridad de lanreótide y octreótido en personas con diagnóstico de gigantismo o de acromegalia. Rep No 106 Bogotá, DC Inst Evaluación Tecnológica en Salud-IETS y Minist Salud y Protección Soc. 2014;1–59.
Lavrentaki A, Paluzzi A, Wass JAH, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9.
Coopmans EC, Postma MR, Wolters TLC, van Meyel SWF, Netea-Maier R, van Beek AP, et al. Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study. J Clin Endocrinol Metab. 2021;106(6):1783–92.
Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol [Internet]. 2018;14(9):552–61. Available from: http://dx.doi.org/10.1038/s41574-018-0058-5
Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab [Internet]. 2014;99(11):3933–51. Available from: file:///Users/nataliabuitrago/Documents/residencia medicina interna/Estudios/Acromegalia Novartis/Artículos/Katznelson L, Laws ER, Jr., Melmed S, et al. Acromegaly- an endocrine society clinical practice guideline. The Journal of clinical endocrinology an
Howlett TA, Willis D, Walker G, Wass JAH, Trainer PJ. Control of growth hormone and IGF1 in patients with acromegaly in the UK: Responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf). 2013;79(5):689–99.
Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859–68.
Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prévost G, et al. Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: Results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282–90.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–9.
Ben-Shlomo A. Pharmacotherapy for Acromegaly. Future Role for Pasireotide? Endocrinol Metab Clin North Am [Internet]. 2015;44(1):35–41. Available from: http://dx.doi.org/10.1016/j.ecl.2014.10.004
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84.
Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary [Internet]. 2021;24(1):1–13. Available from: https://doi.org/10.1007/s11102-020-01091-7
Chiloiro S, Giampietro A, Bianchi A, Tartaglione T, Bima C, Vita MG, et al. Acromegaly can be cured by first-line pasireotide treatment? Endocrine [Internet]. 2019;64(1):196–9. Available from: http://dx.doi.org/10.1007/s12020-019-01874-4
Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, et al. Clinical case seminar: Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab. 2007;92(5):1592–9.
Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al. Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf). 2002;56(1):65–71.
Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: A prospective study. J Clin Endocrinol Metab. 2009;94(10):3746–56.
Ghajar AA, Jones P, Guarda FJ, Faje A, Nicholas A, Miller KK, et al. Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab. 2020;105(3):dgz187.
Öberg K, Lamberts SWJ. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: Past, present and future. Endocr Relat Cancer. 2016;23(12):R551–66.
Chin SO, Ku CR, Kim BJ, Kim SW, Park KH, Song KH, et al. Medical treatment with somatostatin analogues in acromegaly: Position statement. Endocrinol Metab. 2019;34(1):53–9.
Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, García-Dominguez A, Reza-Albarrán AA, et al. The Mexican acromegaly registry: Clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101(11):3997–4004.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. 2015;18(3):385–94.
Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary. 2012;15(3):398–404.
Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007;67(2):282–9.
Kyriakakis N, Seejore K, Hanafy A, Murray RD. Management of persistent acromegaly following primary therapy: The current landscape in the UK. Endocrinol Diabetes Metab. 2020;3(3):1–9.
Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, et al. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: Crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord [Internet]. 2016;16(1):1–10. Available from: http://dx.doi.org/10.1186/s12902-016-0096-8
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Derechos de autor 2021 Revista Colombiana de Endocrinología, Diabetes & Metabolismo